FINHUB Insights

BMY · Q1 FY26 · Mar 31, 2026

Bristol Myers Squibb Q1 FY26: where the revenue came from and where it went

Bristol Myers Squibb Q1 FY26: revenue $11.5B (+3% year over year). Net profit $2.7B. Largest cohort Growth Portfolio $6.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
Apr 30, 2026 10-Q
Sankey diagram of Bristol Myers Squibb's income statement for Q1 FY26: revenue of $11.5 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$11.5B +3% year over year
Gross profit$8.1B 70% margin
Operating profit$-0.5B -5% margin
Net profit$2.7B 23% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 11.5 100% +3%
Growth Portfolio 6.2 54% +12%
Eliquis 4.1 36% +16%
Pomalyst/Imnovid 0.5 4% −22%
Revlimid 0.3 3% −63%
Other Legacy products (b) 0.2 2% −22%
Sprycel 0.1 1% −58%
Abraxane 0.1 1% −52%
Cost of revenue−3.430%
Gross profit8.170% margin−3pp
Research & development−2.623%+3pp
SG&A−1.614%+0pp
Other−4.338%+0pp
Operating profit-0.5-5% margin+0pp
Tax−0.6
Net profit2.723%+1pp
Filing on EDGAR More quarters of BMY

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters